OCX Stock Overview
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.02|
|52 Week High||US$6.25|
|52 Week Low||US$0.84|
|1 Month Change||4.06%|
|3 Month Change||-27.14%|
|1 Year Change||-82.44%|
|3 Year Change||-59.04%|
|5 Year Change||-80.38%|
|Change since IPO||-83.68%|
Recent News & Updates
Revisiting OncoCyte Corp.
We circle back on OncoCyte Corp. for the first time in just over one year. This oncology diagnostic concern has several new products it plans to launch on the near-term horizon. A beneficial owner was a heavy buyer of a recent secondary offering. A full investment analysis is provided in the paragraphs below.
|OCX||US Biotechs||US Market|
Return vs Industry: OCX underperformed the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: OCX underperformed the US Market which returned -20.5% over the past year.
|OCX Average Weekly Movement||8.9%|
|Biotechs Industry Average Movement||13.0%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: OCX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: OCX's weekly volatility (9%) has been stable over the past year.
About the Company
|2009||113||Ronnie, Ron Andrews||https://oncocyte.com|
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.
OncoCyte Fundamentals Summary
|OCX fundamental statistics|
Is OCX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OCX income statement (TTM)|
|Cost of Revenue||US$7.82m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.57|
|Net Profit Margin||-877.90%|
How did OCX perform over the long term?See historical performance and comparison
Is OCX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OCX?
Other financial metrics that can be useful for relative valuation.
|What is OCX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does OCX's PS Ratio compare to its peers?
|OCX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: OCX is good value based on its Price-To-Sales Ratio (15.6x) compared to the peer average (29.1x).
Price to Earnings Ratio vs Industry
How does OCX's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Sales vs Industry: OCX is expensive based on its Price-To-Sales Ratio (15.6x) compared to the US Biotechs industry average (13.8x)
Price to Sales Ratio vs Fair Ratio
What is OCX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||15.6x|
|Fair PS Ratio||13.5x|
Price-To-Sales vs Fair Ratio: OCX is expensive based on its Price-To-Sales Ratio (15.6x) compared to the estimated Fair Price-To-Sales Ratio (13.5x).
Share Price vs Fair Value
What is the Fair Price of OCX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate OCX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate OCX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OCX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is OncoCyte forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OCX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OCX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OCX's revenue (77.5% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: OCX's revenue (77.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OCX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has OncoCyte performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OCX is currently unprofitable.
Growing Profit Margin: OCX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OCX is unprofitable, and losses have increased over the past 5 years at a rate of 28.7% per year.
Accelerating Growth: Unable to compare OCX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: OCX has a negative Return on Equity (-123.7%), as it is currently unprofitable.
Discover strong past performing companies
How is OncoCyte's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: OCX's short term assets ($24.6M) exceed its short term liabilities ($14.0M).
Long Term Liabilities: OCX's short term assets ($24.6M) do not cover its long term liabilities ($75.4M).
Debt to Equity History and Analysis
Debt Level: OCX has more cash than its total debt.
Reducing Debt: OCX's debt to equity ratio has reduced from 22% to 1.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OCX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 29% each year
Discover healthy companies
What is OncoCyte current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OCX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OCX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OCX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OCX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OCX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ronnie, Ron Andrews (61 yo)
Mr. Ronald A. Andrews, Jr., also known as Ronnie or Ron, has been an Independent Director of Precipio, Inc. since March 01, 2021. Mr. Andrews has been the Chief Executive Officer and President of OncoCyte...
CEO Compensation Analysis
Compensation vs Market: Ronnie, Ron's total compensation ($USD2.92M) is above average for companies of similar size in the US market ($USD758.64K).
Compensation vs Earnings: Ronnie, Ron's compensation has increased whilst the company is unprofitable.
Experienced Management: OCX's management team is considered experienced (2.3 years average tenure).
Experienced Board: OCX's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OCX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.7%.
OncoCyte Corporation's employee growth, exchange listings and data sources
- Name: OncoCyte Corporation
- Ticker: OCX
- Exchange: NasdaqGM
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$125.332m
- Shares outstanding: 122.87m
- Website: https://oncocyte.com
Number of Employees
- OncoCyte Corporation
- 15 Cushing
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.